Edition:
United Kingdom

Vital Therapies Inc (VTL.OQ)

VTL.OQ on NASDAQ Stock Exchange Global Select Market

0.22USD
18 Jan 2019
Change (% chg)

$-0.00 (-0.72%)
Prev Close
$0.22
Open
$0.23
Day's High
$0.24
Day's Low
$0.22
Volume
106,035
Avg. Vol
688,996
52-wk High
$9.70
52-wk Low
$0.15

Latest Key Developments (Source: Significant Developments)

Vital Therapies, Immunic Therapeutics Announce Transaction To Create An Inflammatory And Autoimmune Disease Company
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Vital Therapies Inc ::VITAL THERAPIES AND IMMUNIC THERAPEUTICS ANNOUNCE TRANSACTION TO CREATE LEADING INFLAMMATORY AND AUTOIMMUNE DISEASE COMPANY.ENTERED INTO A DEFINITIVE AGREEMENT UNDER WHICH VITAL THERAPIES IS EXPECTED TO ACQUIRE ALL OF OUTSTANDING SHARES IN IMMUNIC.VITAL THERAPIES -CO TO ACQUIRE ALL OF OUTSTANDING SHARES IN IMMUNIC IN EXCHANGE FOR NEWLY ISSUED SHARES OF VITAL THERAPIES IN AN ALL-STOCK TRANSACTION.VITAL THERAPIES-CO'S STOCKHOLDERS TO OWN ABOUT 11% OF COMPANY, CURRENT IMMUNIC STOCKHOLDERS EXPECTED TO OWN ABOUT 89% OF COMPANY IN PROPOSED DEAL.VITAL THERAPIES - DEAL EXPECTED TO CREATE NASDAQ-LISTED BIOPHARMACEUTICAL CO FOCUSED ON ADVANCING IMMUNIC'S PIPELINE OF ASSETS.TRANSACTION HAS BEEN APPROVED BY BOARD OF DIRECTORS OF BOTH COMPANIES AND STOCKHOLDERS OF IMMUNIC.VITAL THERAPIES- WITH SIGNING OF AGREEMENT , RUSSELL J. COX, VITAL THERAPIES' CHIEF EXECUTIVE OFFICER, WILL BE LEAVING COMPANY IN NEAR TERM.UPON CLOSING , COMPANY IS EXPECTED TO OPERATE UNDER NAME IMMUNIC, INC. AND TRADE ON NASDAQ GLOBAL MARKET.VITAL THERAPIES - INVESTOR SYNDICATE INCLUDING LIFE SCIENCES PARTNERS, OMEGA FUNDS COMMITTED TO INVEST ABOUT EUR 26 MILLION IN COMPANY AT CLOSING OF DEAL.COMPANY TO BE LED BY DANIEL VITT, CEO AND PRESIDENT OF IMMUNIC, AND WILL BE HEADQUARTERED IN BOSTON, MA, USA.  Full Article

Vital Therapies Provides Strategic Update
Thursday, 11 Oct 2018 

Oct 11 (Reuters) - Vital Therapies Inc ::VITAL THERAPIES PROVIDES STRATEGIC UPDATE.VITAL THERAPIES INC - COMPANY UNDERWENT A REDUCTION IN FORCE OF APPROXIMATELY 80% OF ITS WORKFORCE.VITAL THERAPIES - HAS RETAINED LADENBURG THALMANN & CO INC AS ITS STRATEGIC FINANCIAL ADVISOR TO ASSIST IN REVIEW OF COMPANY'S BUSINESS AND ASSETS.VITAL THERAPIES INC - BOARD OF DIRECTORS HAS NOW ALSO REDUCED ITS SIZE FROM NINE TO FOUR MEMBERS.VITAL THERAPIES INC - WILL CONTINUE TO EVALUATE NEED FOR ITS REMAINING PERSONNEL THROUGHOUT THIS PROCESS.VITAL THERAPIES - RETAINED LADENBURG THALMANN TO ASSIST IN EXPLORATION OF STRATEGIC OPPORTUNITIES, INCLUDING POTENTIAL SALE OR MERGER OF CO.  Full Article

Vital Therapies Announces Topline Results Of VTL-308 Fail To Achieve Primary And Secondary Endpoints Of Improvement In Survival
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Vital Therapies Inc ::VITAL THERAPIES ANNOUNCES THAT TOPLINE RESULTS OF VTL-308 FAIL TO ACHIEVE PRIMARY AND SECONDARY ENDPOINTS OF IMPROVEMENT IN SURVIVAL.SECONDARY ENDPOINT OF PROPORTION OF SURVIVORS AT STUDY DAY 91 ALSO SHOWED NO STATISTICALLY SIGNIFICANT DIFFERENCE BETWEEN GROUPS.VITAL THERAPIES-DOESNT BELIEVE ELAD SYSTEM CAN BE APPROVED IN US OR EU WITHOUT ADDITIONAL CLINICAL TRIALS THAT WOULD REQUIRE SUBSTANTIAL CAPITAL, TIME.COMPANY WILL CEASE ANY FURTHER DEVELOPMENT OF ELAD SYSTEM AND EXPLORE STRATEGIC OPTIONS.  Full Article

Vital Therapies Reports Loss Per Share Of $0.30
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Vital Therapies Inc ::VITAL THERAPIES ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.30.Q2 EARNINGS PER SHARE VIEW $-0.33 -- THOMSON REUTERS I/B/E/S.CASH AND CASH EQUIVALENTS AT JUNE 30, 2018, TOTALED $31.1 MILLION COMPARED TO $56.9 MILLION AT DECEMBER 31, 2017.  Full Article

Vital Therapies Appoints Russell J. Cox As Chief Executive Officer And Board Member
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Vital Therapies Inc ::VITAL THERAPIES APPOINTS RUSSELL J. COX AS CHIEF EXECUTIVE OFFICER AND BOARD MEMBER EFFECTIVE JANUARY 3, 2018.VITAL THERAPIES INC - COX WILL SUCCEED TERRY WINTERS.  Full Article

Vital Therapies reports Q3 loss per share $0.30
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Vital Therapies Inc ::Vital therapies announces third quarter 2017 financial results.Q3 loss per share $0.30.Q3 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.Vital Therapies-believes current cash position could provide funding through q1 2019, past expected announcement of VTL-308 top-line trial results​.  Full Article

Deals of the day-Mergers and acquisitions

Sept 12 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday: